Revelation Biosciences Financials
This page shows Revelation Biosciences (REVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Repeated equity funding is sustaining a research-driven cash burn while the company keeps a liquid, lightly encumbered balance sheet.
FY2023’s near-breakeven net loss of-$120K did not mark an operating turnaround, because operating loss was still-$8.7M . By FY2025, net loss of-$8.9M sat much closer to operating cash outflow of-$8.3M , meaning reported earnings again resembled the business’s real cash use.
A cash increase in FY2025 was funded externally, not earned internally: financing inflow of
The expense base is still research-heavy: R&D at
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Revelation Biosciences's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Revelation Biosciences carries a low D/E ratio of 0.31, meaning only $0.31 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.41, Revelation Biosciences holds $5.41 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Revelation Biosciences generates a -100.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -319.4% the prior year.
Revelation Biosciences passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Revelation Biosciences generates $0.93 in operating cash flow (-$8.3M OCF vs -$8.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Revelation Biosciences's EBITDA was -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.8% from the prior year.
Revelation Biosciences reported -$8.9M in net income in fiscal year 2025. This represents an increase of 40.7% from the prior year.
Revelation Biosciences earned $-23.95 per diluted share (EPS) in fiscal year 2025. This represents an increase of 97.7% from the prior year.
Cash & Balance Sheet
Revelation Biosciences held $10.7M in cash against $0 in long-term debt as of fiscal year 2025.
Revelation Biosciences had 2M shares outstanding in fiscal year 2025. This represents an increase of 3539.1% from the prior year.
Margins & Returns
Revelation Biosciences's ROE was -100.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 218.8 percentage points from the prior year.
Capital Allocation
Revelation Biosciences invested $4.1M in research and development in fiscal year 2025. This represents an increase of 14.5% from the prior year.
REVB Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.4M | N/A | $923K-30.0% | $1.3M+53.5% | $859K | N/A | $831K-40.4% | $1.4M |
| SG&A Expenses | $1.7M | N/A | $1.0M-10.8% | $1.1M-7.5% | $1.2M | N/A | $966K-14.3% | $1.1M |
| Operating Income | -$3.1M | N/A | -$1.9M+21.1% | -$2.5M-17.5% | -$2.1M | N/A | -$1.8M+28.8% | -$2.5M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | $0 | N/A | $0 | N/A | $0 | $0 |
| Net Income | -$3.0M | N/A | -$1.9M+22.0% | -$2.4M-19.2% | -$2.1M | N/A | -$2.2M+73.3% | -$8.4M |
| EPS (Diluted) | $-2.71 | N/A | $-1.77 | $-7.01+72.3% | $-25.34 | N/A | $-40.15+83.7% | $-246.27 |
REVB Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.0M+29.9% | $11.6M-9.9% | $12.9M+138.3% | $5.4M+35.9% | $4.0M-40.0% | $6.6M-1.8% | $6.7M-45.1% | $12.3M |
| Current Assets | $14.2M+31.4% | $10.8M-15.7% | $12.8M+139.4% | $5.4M+36.5% | $3.9M-40.2% | $6.6M-1.4% | $6.7M-45.4% | $12.2M |
| Cash & Equivalents | $14.1M+31.9% | $10.7M-15.8% | $12.7M+145.6% | $5.2M+39.7% | $3.7M-43.0% | $6.5M-0.6% | $6.5M-45.8% | $12.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.1M-24.5% | $2.7M+46.8% | $1.9M+18.2% | $1.6M+44.0% | $1.1M-43.1% | $1.9M-52.9% | $4.1M-63.5% | $11.1M |
| Current Liabilities | $1.4M-29.1% | $2.0M+7.7% | $1.9M+18.2% | $1.6M+44.0% | $1.1M-43.1% | $1.9M-52.9% | $4.1M-63.5% | $11.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $13.0M+46.6% | $8.9M-19.5% | $11.0M+187.6% | $3.8M+32.8% | $2.9M-38.8% | $4.7M+76.1% | $2.7M+134.4% | $1.1M |
| Retained Earnings | -$52.4M-6.1% | -$49.4M-5.4% | -$46.9M-4.2% | -$45.0M-5.7% | -$42.6M-5.1% | -$40.5M-4.5% | -$38.8M-6.1% | -$36.5M |
REVB Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M-63.4% | -$2.0M-23.8% | -$1.6M+17.2% | -$1.9M+31.3% | -$2.8M+25.4% | -$3.7M+59.5% | -$9.3M-273.5% | -$2.5M |
| Capital Expenditures | $72K | N/A | N/A | N/A | N/A | -$18K-200.0% | $18K | $0 |
| Free Cash Flow | -$3.3M | N/A | N/A | N/A | N/A | -$3.8M+59.4% | -$9.3M-274.2% | -$2.5M |
| Investing Cash Flow | -$72K | N/A | N/A | N/A | N/A | $18K+200.0% | -$18K | $0 |
| Financing Cash Flow | $6.7M+16375.1% | -$41K-100.5% | $9.1M | N/A | N/A | $3.7M-1.5% | $3.7M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
REVB Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -23.2% | N/A | -17.3%+46.6pp | -63.9%+7.3pp | -71.2% | N/A | -83.8%+651.8pp | -735.7% |
| Return on Assets | -20.0% | N/A | -14.8%+30.5pp | -45.3%+6.3pp | -51.7% | N/A | -33.3%+35.1pp | -68.4% |
| Current Ratio | 10.02+4.6 | 5.41-1.5 | 6.92+3.5 | 3.42-0.2 | 3.61+0.2 | 3.43+1.8 | 1.64+0.5 | 1.10 |
| Debt-to-Equity | 0.16-0.1 | 0.31+0.1 | 0.17-0.2 | 0.41+0.0 | 0.38-0.0 | 0.41-1.1 | 1.52-8.2 | 9.76 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Revelation Biosciences profitable?
No, Revelation Biosciences (REVB) reported a net income of -$8.9M in fiscal year 2025.
What is Revelation Biosciences's EBITDA?
Revelation Biosciences (REVB) had EBITDA of -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Revelation Biosciences's return on equity (ROE)?
Revelation Biosciences (REVB) has a return on equity of -100.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Revelation Biosciences's operating cash flow?
Revelation Biosciences (REVB) generated -$8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Revelation Biosciences's total assets?
Revelation Biosciences (REVB) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Revelation Biosciences spend on research and development?
Revelation Biosciences (REVB) invested $4.1M in research and development during fiscal year 2025.
What is Revelation Biosciences's current ratio?
Revelation Biosciences (REVB) had a current ratio of 5.41 as of fiscal year 2025, which is generally considered healthy.
What is Revelation Biosciences's debt-to-equity ratio?
Revelation Biosciences (REVB) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Revelation Biosciences's return on assets (ROA)?
Revelation Biosciences (REVB) had a return on assets of -77.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Revelation Biosciences's cash runway?
Based on fiscal year 2025 data, Revelation Biosciences (REVB) had $10.7M in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Revelation Biosciences's Piotroski F-Score?
Revelation Biosciences (REVB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Revelation Biosciences's earnings high quality?
Revelation Biosciences (REVB) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Revelation Biosciences?
Revelation Biosciences (REVB) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.